Based on the Eyepoint Pharmaceuticals Inc stock forecast from 6 analysts, the average analyst target price for Eyepoint Pharmaceuticals Inc is USD 20.00 over the next 12 months. Eyepoint Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Eyepoint Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Eyepoint Pharmaceuticals Inc’s stock price was USD 6.37. Eyepoint Pharmaceuticals Inc’s stock price has changed by +12.25% over the past week, +2.08% over the past month and -60.58% over the last year.
No recent analyst target price found for Eyepoint Pharmaceuticals Inc
No recent average analyst rating found for Eyepoint Pharmaceuticals Inc
Company Overview Eyepoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Read Less
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its le...Read More
Frequently Asked Questions About Eyepoint Pharmaceuticals Inc (EYPT) Stock
Based on ratings from 6 analysts Eyepoint Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on EYPT's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for EYPT is USD 20.00 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 18.
Unfortunately we do not have enough data on EYPT's stock to indicate if its overvalued.
The last closing price of EYPT's stock was USD 6.37.
The most recent market capitalization for EYPT is USD 0.37B.
Based on targets from 6 analysts, the average taret price for EYPT is projected at USD 20.00 over the next 12 months.
This means that EYPT's stock price may go up by +213.97% over the next 12 months.
We can't find any ETFs which contains Eyepoint Pharmaceuticals Inc's stock.
As per our most recent records Eyepoint Pharmaceuticals Inc has 165 Employees.
Eyepoint Pharmaceuticals Inc's registered address is 480 Pleasant Street, Watertown, MA, United States, 02472.
You can get more information about it from Eyepoint Pharmaceuticals Inc's website at https://eyepointpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Eyepoint Pharmaceuticals Inc (EYPT) Stock
Based on ratings from 6 analysts Eyepoint Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on EYPT's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for EYPT is USD 20.00 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 18.
Unfortunately we do not have enough data on EYPT's stock to indicate if its overvalued.
The last closing price of EYPT's stock was USD 6.37.
The most recent market capitalization for EYPT is USD 0.37B.
Based on targets from 6 analysts, the average taret price for EYPT is projected at USD 20.00 over the next 12 months.
This means that EYPT's stock price may go up by +213.97% over the next 12 months.
We can't find any ETFs which contains Eyepoint Pharmaceuticals Inc's stock.
As per our most recent records Eyepoint Pharmaceuticals Inc has 165 Employees.
Eyepoint Pharmaceuticals Inc's registered address is 480 Pleasant Street, Watertown, MA, United States, 02472.
You can get more information about it from Eyepoint Pharmaceuticals Inc's website at https://eyepointpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EYPT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
